ScholarLens Back to search
2001•Chinese New Drugs JournalRequires access

The efficacy and safety of trimebutine maleate in the treatment of irritable bowel syndrome

Hui Wang

Open publisher page 0 citations

Abstract

Objective:To validate the clinical safety and efficacy of trimebutine maleate(Cerekinon) in treatment of irritable bowel syndrome(IBS).Methods:64 patients with IBS were recruited into the study.After 2 weeks placebo treatment 15 patients were excluded from the study due to symptoms relief.The balance of 49 patients were treated with Cerekinon 200mg,po,tid for 2 weeks.Results:After 2 weeks treatment,the following results were obtained:91.8% reduction in abdominal pain;89.8% reduction in abnormal defecation;86.6% reduction in diarrhoea;81.8% reduction in constipation;and a total effective rate 81.6%.No side effect was observed.Conclusion:Cerekinon is an effective agent for treatment of IBS. [

About this research paper

What this paper is about

Objective:To validate the clinical safety and efficacy of trimebutine maleate(Cerekinon) in treatment of irritable bowel syndrome(IBS).Methods:64 patients with IBS were recruited into the study.After 2 weeks placebo treatment 15 patients were excluded from the study due to symptoms relief.The balance of 49 patients were treated with Cerekinon 200mg,po,tid for 2 weeks.Results:After 2 weeks treatment,the following results were obtained:91.8% reduction in abdominal pain;89.8% reduction in abnormal defecation;86.6% reduction in diarrhoea;81.8% reduction in constipation;and a total effective rate 81.6%.No side effect was observed.Conclusion:Cerekinon is an effective agent for treatment of IBS. [

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To validate the clinical safety and efficacy of trimebutine maleate(Cerekinon) in treatment of irritable bowel syndrome(IBS).Methods:64 patients with IBS were recruited into the study.After 2 weeks placebo treatment 15 patients were excluded from the study due to symptoms relief.The balance of 49 patients were treated with Cerekinon 200mg,po,tid for 2 weeks.Results:After 2 weeks treatment,the following results were obtained:91.8% reduction in abdominal pain;89.8% reduction in abnormal defecation;86.6% reduction in diarrhoea;81.8% reduction in constipation;and a total effective rate 81.6%.No side effect was observed.Conclusion:Cerekinon is an effective agent for treatment of IBS. [

Key concepts: Medicine, Irritable bowel syndrome, Constipation, Defecation, Placebo, Abdominal pain, Internal medicine, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The efficacy and safety of trimebutine maleate in the treatment of irritable bowel syndrome — Research Paper | ScholarLens